/
Oncology
Chronic Lymphocytic Leukemia
72
Pipeline Programs↗
176
Active Trials↗
80
Companies Involved↗
Chronic Lymphocytic Leukemia is a moderately active landscape with 72 programs across 80 companies. The most active players are Lomond Therapeutics Holdings, Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeOne Medicines. 14 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 19
Phase 235
Phase 314
Approved
No programs
Analysis
Modality Breakdown
69%
Small molecule
42 of 61 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 61 classified programs, each share of the total. Modality classified for 93% of 72 pipeline programs.
Analysis
Trial Status
706
clinical trials
Completed359 · 51%
Terminated100 · 14%
Recruiting80 · 11%
Active, not recruiting77 · 11%
Withdrawn39 · 6%
Unknown status28 · 4%
Other23 · 3%
Clinical Trials
Trial Activity
706 trials
Page 1 of 48
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)